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SUMMARY 
Backgrounds: Neuroendocrine neoplasms in hepatobiliary organs are very rare, but several cases of 
mixed adenoneuroendocrine carcinoma (MANEC) have been reported. In this study, we 
characterized the neuroendocrine component of biliary MANEC. Materials and methods: A total of 
274 cases of biliary cancer including 17 intrahepatic cholangiocarcinomas (CCs), 15 hepatic hilar 
CCs without preceding hepatobiliary disease, 55 hepatic hilar CCs with hepatolithiasis, 49 
gallbladder cancers, 53 extrahepatic CCs, and 85 hepatocellular carcinomas (HCC) were examined 
for an neuroendocrine component by immunohistochemistry with neuroendocrine markers 
(chromogranin A and synaptophysin). In the MANEC cases, in addition to a close histological 
examination, the proliferative activity and the expression of somatostatin receptor 2A were also 
evaluated. Results: In addition to an ordinary adenocarcinoma, an neuroendocrine component 
occupying more than 30% of the entire tumor was also found in 4% (2/55 cases) of hepatic hilar 
cholangiocarcinomas with hepatolithiasis, 10% (5/49 cases) of gallbladder cancers, and 4% (2/53 
cases) of extrahepatic cholangiocarcinomas, but not in the intrahepatic cholangiocarcinomas, hilar 
cholangiocarcinomas without preceding hepatobiliary disease, and hepatocellular carcinomas. Two 
cases were positive for somatostatin receptor 2A. The adenocarcinoma components were 
predominately located at the surface of the tumors and the majority of stromal and vascular invasion 
and lymph node metastasis involved neuroendocrine components showing features of 
neuroendocrine tumor G2 or neuroendocrine carcinomas (NECs). NEC components showed higher 
proliferative activity on Ki67 immunostaining, compared to the adenocarcinoma components. 
Conclusion: Biliary MANECs are found in hepatic hilar cholangiocarcinomas with hepatolithiasis, 
gallbladder cancers, and extrahepatic cholangiocarcinomas and show a characteristic histology. 
Since the neuroendocrine component in biliary MANEC defines the prognosis, it is important to 
identify it and consider the indications for adjunctive therapy with somatostatin analogues. 
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INTRODUCTION 
Neuroendocrine neoplasms including carcinoid tumors are commonly found in several organs 
including the pancreas and gastrointestinal tract. The World Health Organization (WHO) 
classification (2000)[1] has been widely used to categorize neuroendocrine tumors (NETs) for all 
anatomical sites and NETs are histologically and biologically classed as well-differentiated 
neuroendocrine tumors, well-differentiated neuroendocrine carcinomas (low grade malignancy), 
poorly differentiated neuroendocrine carcinomas (high grade malignancy), and mixed 
exocrine-endocrine carcinomas [2,3]. The European Neuroendocrine Tumor Society (ENETS) has 
recently proposed two complementary classification tools - a grading classification and a site-specific 
staging system [4]. The recent WHO classification (2010) [5,6], moreover, strengthens the appreciation 
of 3 concepts: tumor heterogeneity, tumor differentiation, and malignancy. According to the WHO 
classification (2010), neuroendocrine neoplasms in the digestive system including gallbladder and 
extrahepatic bile ducts are classed as NET G1 (carcinoid, mitotic count < 2 per 10 high powder 
fields [HPF] and/or ≤ 2% Ki67 index), NET G2 (mitotic count 2-20 per 10 HPF and/or 3-20% Ki67 
index), NET G3 (neuroendocrine carcinoma [NEC], mitotic count >20 per 10 HPF and/or >20% 
Ki67 index), and mixed adenoneuroendocrine carcinoma (MANEC). This classification reflects the 
prognosis of patients with neuroendocrine neoplasms as well as biologic potential and is based on 
general pathological findings such as tumor size, differentiation, mitotic index, perineural or 
vascular invasion, metastasis, and local invasion to muscular propria (gastrointestinal tracts) and 
adjacent organs [2,3]. Typical carcinoids showing benign behavior and atypical carcinoids showing 
malignant features are equated with NET G1 and NET G2, respectively. NEC includes small cell 
carcinoma and large cell neuroendocrine carcinoma (LCNEC) considered as homologous to the 
pulmonary counterpart [2,3]. 
Neuroendocrine cells and tumors are characterized by the expression of markers such as 
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chromogranin A and synaptophysin and the production of hormonal substances including serotonin, 
gastrin, and somatostatin. However, because some neuroendocrine neoplasms lack distinct or 
functional hormones, a functional classification is of little value. Recently, it was demonstrated that 
somatostatin analogues such as SOM230 and octreotide are the best therapeutic option for 
neuroendocrine neoplasms, because they reduce hormone-related symptoms and also have antitumor 
effects [7,8]. A neuroendocrine neoplasm demonstrated to possess the receptor for somatostatin 
(SSTR) is a good candidate for treatment with a somatostatin analogue. Therefore, the pathological 
differentiation and diagnosis of neuroendocrine neoplasms is important for chemotherapy after the 
resection of a tumor [7]. Tumors originating from the intrahepatic and extrahepatic biliary trees are 
mostly malignant carcinomas, in particular adenocarcinomas, irrespective of their etiology. 
Physiologically, a few neuroendocrine cells resembling enterochromaffin-like cells exist in the 
biliary tree, particularly in the large bile ducts and peribiliary glands of the hepatic hilus [9], but 
cases of neuroendocrine neoplasms in hepatobiliary organs are extremely rare. Carcinoids of the 
gallbladder and the extrahepatic biliary tract represent 0.2% and 0.01% of all carcinoids, respectively 
[1].  
To date, several cases of hepatobiliary neuroendocrine neoplasms, mostly biliary 
adenocarcinomas accompanying an neuroendocrine component (MANEC), have been reported 
[10-14], but the neuroendocrine component in biliary MANEC is not well characterized. In this 
study, we surveyed neuroendocrine neoplasms in hepatobiliary tumors and characterized 
hepatobiliary MANEC. Our final aim was to assess the clinicopathological significance of 
neuroendocrine components in hepatobiliary MANEC including the prognosis after the surgical 
resection of tumors. 
 
MATERIALS and METHODS 
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Patients and tissue preparations 
A total of 274 cases of biliary cancer including 17 intrahepatic cholangiocarcinomas (CC), 
15 hepatic hilar CCs without preceding hepatobiliary disease, 55 hepatic hilar CCs with 
hepatolithiasis, 49 gallbladder cancers, 53 extrahepatic CCs, and 85 hepatocellular carcinomas 
(HCCs) were examined in this study. All materials were surgically resected hepatobiliary specimens 
retrieved from the surgical files of our laboratories and affiliated hospitals. These tissue specimens 
containing tumorous lesions were immediately fixed in 10% neutral-buffered formalin and 
embedded in paraffin. Several 4μm-thick sections were prepared from each paraffin-embedded block 
and either routinely stained for histologic evaluation or processed for immunohistochemical analysis. 
 
Immunohistochemistry 
Using representative cancerous sections from each case and also cases involving 
neuroendocrine neoplasms, all sections including lymph nodes were prepared for pathological 
diagnosis, and the immunohistochemical staining of neuroendocrine markers (chromogranin A and 
synaptophysin) was performed for surveying the presence of neuroendocrine neoplasms. Moreover, 
in cases involving neuroendocrine neoplasms, a cell proliferative marker (Ki67) and SSTR type 2A 
(SSTR2A) were also immunostained to examine the cell kinetics as a marker of malignancy and the 
indications for treatment with somatostatin analogues.  
Deparaffinized and rehydrated sections were pretreated for antigen retrieval prior to 
staining (Table 1). Following endogenous peroxidase blocking and incubation in normal goat serum 
(1:10; Vector Lab, Burlingame, CA) for 20 min, these sections were incubated at 4°C overnight with 
primary antibodies (Table 1), and then at room temperature for 1 hour with goat anti-mouse or 
anti-rabbit immunoglobulins conjugated to a peroxidase-labeled dextran polymer (Envision, Dako 
Japan). After a benzidine reaction, sections were weakly counterstained with hematoxylin. As a 
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negative control, nonimmune serum was used for the primary antibody. This procedure consistently 
resulted in no staining. 
 
Examination of hepatobiliary neuroendocrine neoplasms 
Chromogranin A- and/or synaptophysin-positive cells were evaluated as neuroendocrine cells 
and a neuroendocrine neoplasm was basically defined as a well- to poorly differentiated tumor 
composed of cells with features similar to those of the normal gut endocrine cell, showing the 
diffuse and distinct staining for chromogranin A and/or synaptophysin [5]. The grading for 
neuroendocrine neoplasms (NET G1, G2, or G3 [NEC]) was performed on the basis of morphological 
criteria and the assessment of the proliferative fraction according to the ENETS scheme [4]: we 
established a Ki67 labeling index as a percentage of 2000 cells counted in the area of strongest nuclear 
labeling and mitotic count per 10 high powder fields (HPFs) by evaluating at least 50 HFPs. In MANEC 
cases, at least 30% of the main lesion excluding any broad invasive area had to be made up of either 
component for this definition to apply [5] and the following pathological features were also 
examined; tumor size, gross classification (mass forming, periductal infiltrating, or intraductal 
growth), depth of invasion, lymphatic, vascular, and perineural invasion (present or absent, and if 
present, its histology), and lymph node metastasis (present or absent, and if present, its histology).  
 
RESULTS 
Staining pattern of chromogranin A and synaptophysin 
Hepatobiliary tumors merely contain cells positive for the neuroendocrine marker 
chromogranin A or synaptophysin. However, in some biliary tumors, the positive cells were scattered 
and sometimes clustered within tumors and extended within the biliary epithelium of adjacent 
non-neoplastic bile ducts (Fig.1). Some neuroendocrine cells resembling enterochromaffin-like cells 
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morphologically were also found (Fig.1). The scattering and/or clustering of these neuroendocrine 
cells was found in 12 of 55 hepatic hilar CCs with hepatolithiasis, 19 of 49 gallbladder cancers, and 
13 of 53 extrahepatic CCs, but not in HCCs, intrahepatic CCs, or hepatic hilar CCs without 
preceding hepatobiliary disease (Table 2). 
Clinicopathological features of the neuroendocrine component in hepatobiliary MANEC 
No cases of HCC, intrahepatic CC, and hepatic hilar CC without preceding hepatobiliary 
disease included neuroendocrine components. In contrast, hepatic hilar CC with hepatolithiasis, 
gallbladder cancer, and extrahepatic CC accompanied neuroendocrine components in addition to 
ordinary adenocarcinoma in 4%, 10%, and 4% of cases, respectively (Table 2). A summary of a total 
of 9 cases of biliary MANEC found in this study is shown in Table 3. As shown in Figs.2-4, 
representative findings of these MANEC cases showed that the adenocarcinoma component was 
located at the surface of tumors and the majority of the stromal invasion including vascular invasion 
and lymph node metastasis involved neuroendocrine components. These components were NET G2 
or NEC, the tumor cells of which had a round- or oval-shaped nucleus and "salt-and-pepper" pattern 
of nuclear chromatin, general characteristics of neuroendocrine cells. NET G1 was not found in any 
cases (Table 3). Cases of NEC showed morphological features of small cell carcinoma or large cell 
neuroendocrine carcinoma, broadly typical of lung cancer. In biliary MANEC, the components 
showing the deepest invasion were neuroendocrine neoplasms and vascular and perineural invasion 
also involved neuroendocrine components. Moreover, several other characteristics were evident as 
follows. The NEC (LCNEC) component in Case 1 had widespread necrosis. In Case 2 composed of 
an uniformly well-differentiated tubular adenocarcinoma, a neuroendocrine marker-positive tubular 
component was also found in an invasive area (Fig.5). Although the Ki67 index was less than 2%, the 
NET in Case 2 was categorized as NET G2 according to the morphology and mitotic index. The Ki67 
index in Case 3 was less than 20%, but this case was regarded as NEC in consideration of the small cell 
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carcinoma-like morphology with necrosis and mitotic index. The NEC component in Case 4 had the 
highest proliferative activity among the biliary MANEC cases examined in this study. The Ki67 index in 
Case 5 was less than 2%, but this tumor was regarded as NET G2 based on morphology and the mitotic 
index (Fig.2). In Case 6, the NEC component (small cell carcinoma) had conspicuous necrosis (Fig.3) 
and the ordinary adenocarcinoma as well as NEC component also showed distinct stromal and 
vascular invasion. The NEC component (LCNEC) in Case 7 had widespread necrosis. Cases 8 and 9 
were MANEC cases arising from the preceding hepatolithiasis and the NEC component (LCNEC) in 
Case 9 clearly had necrosis. 
Immunohistochemistry revealed that Ki67-positive cells were scattered in the 
neuroendocrine component as well as ordinary adenocarcinoma, and in particular, many positive 
tumor cells were found in NEC (Fig.6). Quantitative evaluation also confirmed that the NEC 
component constantly showed high proliferative activity, compared with the adenocarcinoma 
component in each case (Fig.6). SSTR2A expression was found in the cytoplasm and membrane of 
tumor cells of the adenocarcinoma and neuroendocrine components. However, significant 
membranous expression [7] was restricted to the neuroendocrine component and 2 cases of biliary 
MANEC clearly expressed SSTR2A with a NEC histology (Fig.7 and Table 3). 
 
DISCUSSION 
Several cases of hepatobiliary neuroendocrine neoplasms including carcinoid tumors have 
been reported, but most involve hepatic carcinoids or biliary neuroendocrine neoplasms arising from 
or accompanying ordinary adenocarcinomas, mostly in patients with gallbladder cancer and 
extrahepatic CC [10-14]. One case of hepatic NET G1 (carcinoid tumor), but no pure biliary 
neuroendocrine neoplasms without ordinary CC, has been registered in our laboratories and 
affiliated hospitals. In this study, we primarily surveyed the presence of neuroendocrine neoplasms 
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in hepatobiliary tumors (CC and HCC) using immunohistochemistry for chromogranin A and 
synaptophysin. CD56 (NCAM) is also used as a neuroendocrine marker, but biliary epithelial cells in 
intrahepatic small bile ducts, particularly bile ductules, and their tumors are positive for CD56 [15]. 
Therefore, CD56 is not suitable for the identification of neuroendocrine neoplasms in biliary tumors. 
Consequently, as for intrahepatic neuroendocrine neoplasms, no cases of HCC or intrahepatic CC 
accompanying neuroendocrine neoplasms were found in this study, though one case of hepatic 
carcinoid was registered in our files. This finding is very interesting when considering the 
tumorigenesis of intrahepatic neuroendocrine neoplasms such as hepatic carcinoid; intrahepatic 
neuroendocrine neoplasms are unlikely to originate from hepatocytes, cholangiocytes in intrahepatic 
small bile ducts, and their carcinomas (HCC and intrahepatic CC). Therefore, an association between 
hepatic stem cells, that is, multipotential progenitor cells possessing the ability to differentiate into 
various cell types including neuroendocrine cells, and heterotopic neuroendocrine tissue possibly 
remains in the tumorigenesis of hepatic neuroendocrine neoplasms. In contrast, the proliferation of 
neuroendocrine cells and the presence of biliary neuroendocrine neoplasms accompanied by biliary 
adenocarcinoma were found in hepatic hilar CC with hepatolithiasis in addition to gallbladder cancer 
and extrahepatic CC. This finding is also of interest when considering the tumorigenesis of biliary 
neuroendocrine neoplasms and suggests that preceding chronic inflammation, particularly 
lithiasis-associated inflammation, and the accidental proliferation of neuroendocrine cells are closely 
associated with the histogenesis of biliary neuroendocrine neoplasms. The absence of cases of 
hepatic hilar CC without preceding hepatobiliary disease supports this speculation. As for the 
incidence, among biliary cancers, gallbladder cancers most often accompany neuroendocrine neoplasms 
in 10% (5/49) of cases. In this study, we surveyed cases of biliary cancer and collected MANEC cases 
from affiliated hospitals which specialize in hepatobiliary diseases. Therefore, the possibility of a high 
incidence compared with that in the general population could not excluded. However, we recently 
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encountered an additional 2 cases of MANEC in gallbladder after completing this study (not included 
herein). Moreover, cases originally diagnosed as a poorly differentiated component (Case 4) or ordinary 
adenocarcinoma component (Case 2) were included in the biliary MANEC cases found in this study. 
Therefore, we speculate that biliary MANEC cases are no that rare. Pathologists should take into account 
the presence of a neuroendocrine component during the pathological diagnosis of biliary cancers. 
In the new WHO classification system, neuroendocrine neoplasms in the digestive system 
are classed as NET G1 including carcinoid tumor, NET G2, and NEC [5]. This classification also 
applies to biliary neuroendocrine neoplasms [6], but NET G1 was not found in any neuroendocrine 
components of biliary MANEC morphologically. All neuroendocrine components of biliary 
MANEC found in this study belonged to NET G2 or NEC. The malignant grade of neuroendocrine 
neoplasms is generally based on the size of the tumor and cell kinetics (Ki67 labeling index) in 
addition to tumor morphology [2,3], but there is still no broadly accepted definition of malignant 
grade in biliary neuroendocrine neoplasms. Because all neuroendocrine components were found in 
invasive areas of biliary MANEC, it is difficult to define them by the size of a sole neuroendocrine 
component. However, in this study, neuroendocrine components of biliary MANEC could be 
classified according to morphology and cell kinetics. That is, NET G2 and NEC show different 
levels of cell proliferation. Ki67 indices of NEC were constantly higher than those of NET G2 and 
also those of background adenocarcinoma components. This finding suggests that NET G2 and NEC 
could be distinguished by morphological atypia and proliferating activity without information on the 
size of neuroendocrine components in biliary MANEC. It is speculated that biliary tumors 
containing NEC have a poor prognosis based on histological evaluation. We tried to confirm this 
using a Kaplan-Maier analysis, but the number of biliary MANECs was too small. Moreover, 
because the prognosis of biliary tumors appreciably differed with the location in the biliary tree, it 
was difficult to comprehensively analyze the biliary MANECs found in this study. 
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This study revealed that biliary MANECs showed a very characteristic histology, that is, the 
surface of the tumor was an ordinary adenocarcinoma and the neuroendocrine component was 
located in an area of vascular and perineural invasion, and lymph node metastasis always involved 
neuroendocrine components. Moreover, the NEC component showed high proliferative activity, 
compared with the adenocarcinoma component, suggesting that neuroendocrine components, 
particularly NEC, in biliary MANEC could prescribe the prognosis. Among the biliary MANECs 
examined in this study, 2 showed the expression of SSTR2A in NEC, a good indication for the use of 
somatostatin analogues as adjunctive therapy after surgery. 
In this study, HCC, intrahepatic CC, and hepatic hilar CC without preceding hepatobiliary 
disease contained no neuroendocrine components, but some cases of hepatic hilar CC with 
hepatolithiasis, gallbladder cancer, and extrahepatic CC had neuroendocrine components, some of 
which were a high grade malignancy such as neuroendocrine neoplasm (NEC) and SSTR2A-positive 
NEC. Pathologists must be aware of the poor prognosis and of cases indicating the need for adjunct 
therapy including somatostatin analogues after surgical resection. 
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Table 1.  Primary antibodies used in this study 
        
Antibody Concentration Antigen retrieval Supplier 
chromogranin A (Ms) 0.5 μg/ml no treatment  Dako Japan 
Synaptophysin (Ms)  5 μg/ml MW(citrate buffer) Dako Japan 
Ki67 (Ms)  0.22 μg/ml MW(EDTA buffer) Dako Japan 
SSTR2A (Rb)   diluted 1:1000 AC(citrate buffer) Gramsch Laboratories
Ms, mouse monoclonal; Rb, rabbit polyclonal; AC, autoclaved; MW, microwave; 




Table 2.   Frequency of neuroendocrine cells and neoplasms in hepatobiliary tumors 
      
         Neuroendocrine components 
Original diagnosis neuroendocrine cell neuroendocrine neoplasm 
  positive / total cases positive / total cases 
Intrahepatic CC 0/17 (0%) 0/17 (0%) 
hepatic hilar CC without preceding 
hepatobiliary diseases 
0/15 (0%) 0/15 (0%) 
hepatic hilar CC associated with 
hepatolithiasis 
12/55 (22%) 2/55 (4%) 
gallbladder cancer 19/49 (39%) 5/49 (10%) 
extrahepatic CC 13/53 (25%) 2/53 (4%) 
hepatocellular carcinoma 0/85 (0%) 0/85 (0%) 
CC, cholangiocarcinoma. 
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Table 3.  Cases of biliary MANEC 
          
  Case 1 Case 2 Case 3 Case 4 
Age, Gender 60's, Male 80's, Female 70's, Female 70's, Female 
Location 
extrahepatic   
bile duct 
extrahepatic     
bile duct 
gallbladder gallbladder 
precursor lesion   cholecystolithiasis 
tumor size 2.2x1.5cm 1.5x1.2 3.5x2.5cm 4.5x1.0cm 
gross classification  mass forming mass forming mass forming mass forming 
Histology of 
adenocarcinoma 
pap-wel wel wel pap-wel 
Histology of NET NEC, LCNEC 
NET G2, 
adenocarcinoma-like 




neuroendocrine marker  
+ ++ ++ + 
Mitotic index of NET  
(mitotic count/10 HPF) 
53 7 59 137 
Ki67 index of NET (%) 22.3 1.2 12.3 32.3 
depth of invasion 
(histology)   
exposure from 
serosa (NET) 
invasion to pancreas 
(NET) 






+ (NET) + (NET) + (NET) + (NET) 
vascular invasion 
(histology) 
+ (NET) + (NET) + (NET) + (NET) 
perineural invasion 
(histology) 
+ (NET) + (NET) + (NET) － 
lymph node metastasis 
(histology) 
+ (NET) － + (NET) － 
SSTR2A in NET +  － － － 
pap, papillary adenocarcinoma. wel, well-differentiated adenocarcinoma. LCNEC, large cell neuroendocrine 
carcinoma. HPF, high powder field. NET G2 and NEC (WHO classification, 2010). 
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a sequel of Table 3 
 
          
Case 5 Case 6  Case 7 Case 8 Case 9 
70's, Female 60's, Female 50's, Female 60's, Male 70's Female 
gallbladder gallbladder gallbladder hepatic hilum hepatic hilum 
cholecystolithiasis cholecystolithiasis hepatolithiasis hepatolithiasis 
4.5x2.5cm 1.5x1.5cm 15x12cm >2.5cm >2.8cm 
mass forming mass forming mass forming mass forming mass forming 
wel pap-wel wel wel wel 
NET G2, atypical 
carcinoid 
NEC, small cell 
carcinoma 
NEC, LCNEC 
NET G2, atypical 
carcinoid 
NEC, LCNEC 
++ + + + + 
4 95 42 15 76 









+ (NET and 
adenocarcinoma)
+ (NET) + (NET) + (NET) 
－ 
+ (NET and 
adenocarcinoma)
+ (NET) － － 
+ (NET) + (NET) + (NET) － － 
－ 
+ (NET and 
adenocarcinoma)
+ (NET) unspecified unspecified 
－ － +  － － 
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Fig.1  Immunohistochemistry for chromogranin A. Chromogranin A-immunoreactive 
neuroendocrine cells are scattered in non-neoplastic biliary epithelium of gallbladder cancer 
(A) and adenocarcinoma of extrahepatic cholangiocarcinoma (B). Some neuroendocrine cells 
resembling enterochromaffin-like cells morphology which show a triangular shape and are 
located in the basement membrane, are also found (arrow). Original magnification, x200. 
 
Fig.2  Gallbladder cancer with neuroendocrine tumor (NET) G2 (WHO classification, 2010) (Case 
5 in Table 3). Although the surface of the tumor is an ordinary adenocarcinoma (A, arrow) 
(higher magnification, D), the invasive component shows a different histology and 
chromogranin A-positivity (A and B, *). Tumors show a trabecular pattern and consist of 
small monotonous cells with mild atypia, indicating atypical carcinoid (C). (A), (B), and (D) 
are H&E staining. (B) immunohistochemistry for chromogranin A. Original magnification, 
(A) and (B), x20; (C), x200; and (D), x100. 
 
Fig.3  Gallbladder cancer with neuroendocrine carcinoma (NEC) (WHO classification, 2010) (Case 
6 in Table 3). A solid component is found within the adenocarcinoma area (A, *). The solid 
part consists of intermediate-sized round cells with nuclear molding and scanty cytoplasm 
resembling small cell carcinoma of the lung (B). Several mitoses (arrowheads) and necrosis 
(N) are found (B). Original magnification, (A), x20; (B), x400. 
 
Fig.4  Hepatic hilar cholangiocarcinoma associated with hepatolithiasis accompanying 
neuroendocrine carcinoma (NEC) (WHO classification, 2010) (Case 9 in Table 3). An 
ordinary adenocarcinoma (A, arrow) is found in the lumen of a hepatic hilar bile duct, but the 
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proliferating invasive nest shows solid sheets (A, *). The latter part consists of uniform and 
large-sized tumor cells resembling large cell neuroendocrine carcinoma of the lung (B). 
Arrowheads denote mitoses. Original magnification, (A), x20; (B), x400. 
 
Fig.5 Extrahepatic cholangiocarcinoma with neuroendocrine tumor (NET) G2 (WHO classification, 
2010) showing adenocarcinoma morphology (Case 2 in Table 3). The tumor is histologically 
an ordinary adenocarcinoma (A and C), but diffusely positive for chromogranin A except at 
the surface (B). (A) and (C) H&E staining. (B) Immunohistochemistry for chromogranin A. 
Original magnification, (A) and (B), x20; (C), x200. 
 
Fig.6  Comparative analysis of cell kinetics between adenocarcinomas and neuroendocrine 
neoplasms. Many Ki-67-positive cells are found within neuroendocrine carcinoma (NEC, 
large cell neuroendocrine carcinoma type)(WHO classification, 2010) (A, arrow, and B), but 
rarely in adenocarcinomas (A, upper left). In two cases of neuroendocrine tumor (NET) G2 
(WHO classification, 2010), there is no significant difference in the percentage of 
Ki67-positive cells (Ki67 index) between adenocarcinoma and NET G2, but in other all cases, 
particularly NEC, the indices are increased in neuroendocrine components (C). 
Immunohistochemistry for Ki67 (A and B). Original magnification, (A), x20; (B), x100. 
 
Fig.7  Somatostatin receptor 2A (SSTR2A)-positive case (Case 1 in Table 3). An intense 
membranous pattern is found in tumor cells (large cell neuroendocrine carcinoma type). 
Immunohistochemistry for SSTR2A. Original magnification, x400. 
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